NCT04729751Phase 2Completed

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).

Study sponsor: Mirum Pharmaceuticals, Inc. · MIRM

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2024-12-17Actual
Enrollment · participants27Actual
Source updated2026-06-02Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Frequency of treatment-emergent adverse events [TEAEs]. After: Measure: Frequency of Treatment-emergent Adverse Events [TEAEs].

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview